09 July 2026
09 July 2026
The Alturion system combines advanced imaging and AI-driven workflow to help clinicians maintain consistent results.
The 4TAZPower study will follow participants with Barth syndrome for 72 weeks to assess the efficacy and safety.
The partnership will connect Evogene’s AI-based ChemPass AI with the BCDD’s laboratory infrastructure.
The trial will enrol around 280 patients at up to 40 locations in the US and the Netherlands.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
